<DOC>
	<DOCNO>NCT00005943</DOCNO>
	<brief_summary>RATIONALE : Inserting gene interleukin-2 person 's melanoma cell may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness gene therapy treat patient metastatic melanoma .</brief_summary>
	<brief_title>Gene Therapy Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose liposome complexed staphylococcal enterotoxin B interleukin-2 plasmid DNA patient metastatic melanoma . II . Determine local gene expression tumor tissue patient population treat regimen . III . Determine plasmid DNA detect circulation follow intratumoral injection regimen patient population . IV . Evaluate antitumor immune response induce treatment regimen patient . V. Characterize clinical response treatment regimen term tumor size histology patient . VI . Determine clinical response treatment regimen term complete remission , partial remission , stable disease , disease progression patient . OUTLINE : This dose escalation study . Patients receive intratumoral liposome complexed staphylococcal enterotoxin B ( SEB ) interleukin-2 ( IL-2 ) plasmid DNA injection 1-3 tumor nodule every 2 week . Treatment continue 6 course absence disease progression unacceptable toxicity . Patients complete regression therapy may receive additional therapy previously untreated tumor nodule . Patients partial response 4 week follow last injection may continue therapy every 4 week residual tumor remain . Cohorts 3 patient receive escalate dos SEB IL-2 plasmid DNA maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 6 patient experience dose limit toxicity . Patients follow death . PROJECTED ACCRUAL : A total 18 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma unresponsive standard therapy curative therapy exist No primary ocular melanoma At least one cutaneous metastatic lesion measure least 1 cm diameter No untreated brain metastasis MRI CT scan PATIENT CHARACTERISTICS : Age : Over 18 Performance status : SWOG 01 Life expectancy : Greater 2 month Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL No active , acute , chronic hepatitis Renal : Creatinine le 2.0 mg/dL Cardiovascular : No unstable angina complicate cardiovascular disease would preclude catheterization Immunologic : No active autoimmune disease infection Peripheral blood mononuclear cell proliferative response 1 microgram/mL staphylococcal enterotoxin B vitro , stimulation index least 5 Other : HIV negative No uncontrolled diabetes mellitus No psychiatric illness would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior anticancer therapy No concurrent glucocorticosteroids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>